Urinary System Carcinoma — Trials

Urinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 670
Recruiting: 353
Ph III recruiting: 41
Growth YoY: +12.6%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (391)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07756008	Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer	not yet recruiting	Phase 2 / Phase 3	114	Tianjin Medical University Second HospitalOTHER	1	Aug 10, 2026	clinicaltrials
NCT07689240	Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma	not yet recruiting	Phase 3	400	National Cancer Institute (NCI)NIH	0	Jul 8, 2026